Acute megakaryoblastic leukemia natural history, complications and prognosis: Difference between revisions
No edit summary |
|||
Line 2: | Line 2: | ||
{{Acute megakaryoblastic leukemia}} | {{Acute megakaryoblastic leukemia}} | ||
=== Natural History: === | ===<u>Natural History:</u>=== | ||
* Clonal proliferation of early megakaryoblasts in the bone marrow results in acute megakaryoblastic leukemia (AMKL).<ref name="pmid11001891">{{cite journal| author=Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH | display-authors=etal| title=Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. | journal=Blood | year= 2000 | volume= 96 | issue= 7 | pages= 2405-11 | pmid=11001891 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11001891 }}</ref> It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.<ref name="GassmannLöffler2009">{{cite journal|last1=Gassmann|first1=Winfried|last2=Löffler|first2=Helmut|title=Acute Megakaryoblastic Leukemia|journal=Leukemia & Lymphoma|volume=18|issue=sup1|year=2009|pages=69–73|issn=1042-8194|doi=10.3109/10428199509075307}}</ref> | *Clonal proliferation of early megakaryoblasts in the bone marrow results in acute megakaryoblastic leukemia (AMKL).<ref name="pmid11001891">{{cite journal| author=Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH | display-authors=etal| title=Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. | journal=Blood | year= 2000 | volume= 96 | issue= 7 | pages= 2405-11 | pmid=11001891 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11001891 }}</ref> It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.<ref name="GassmannLöffler2009">{{cite journal|last1=Gassmann|first1=Winfried|last2=Löffler|first2=Helmut|title=Acute Megakaryoblastic Leukemia|journal=Leukemia & Lymphoma|volume=18|issue=sup1|year=2009|pages=69–73|issn=1042-8194|doi=10.3109/10428199509075307}}</ref> | ||
* In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the GIMEMA trial.<ref name="PaganoPulsoni2002">{{cite journal|last1=Pagano|first1=L|last2=Pulsoni|first2=A|last3=Vignetti|first3=M|last4=Mele|first4=L|last5=Fianchi|first5=L|last6=Petti|first6=MC|last7=Mirto|first7=S|last8=Falcucci|first8=P|last9=Fazi|first9=P|last10=Broccia|first10=G|last11=Specchia|first11=G|last12=Di Raimondo|first12=F|last13=Pacilli|first13=L|last14=Leoni|first14=P|last15=Ladogana|first15=S|last16=Gallo|first16=E|last17=Venditti|first17=A|last18=Avanzi|first18=G|last19=Camera|first19=A|last20=Liso|first20=V|last21=Leone|first21=G|last22=Mandelli|first22=F|title=Acute megakaryoblastic leukemia: experience of GIMEMA trials|journal=Leukemia|volume=16|issue=9|year=2002|pages=1622–1626|issn=0887-6924|doi=10.1038/sj.leu.2402618}}</ref> | *In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the GIMEMA trial.<ref name="PaganoPulsoni2002">{{cite journal|last1=Pagano|first1=L|last2=Pulsoni|first2=A|last3=Vignetti|first3=M|last4=Mele|first4=L|last5=Fianchi|first5=L|last6=Petti|first6=MC|last7=Mirto|first7=S|last8=Falcucci|first8=P|last9=Fazi|first9=P|last10=Broccia|first10=G|last11=Specchia|first11=G|last12=Di Raimondo|first12=F|last13=Pacilli|first13=L|last14=Leoni|first14=P|last15=Ladogana|first15=S|last16=Gallo|first16=E|last17=Venditti|first17=A|last18=Avanzi|first18=G|last19=Camera|first19=A|last20=Liso|first20=V|last21=Leone|first21=G|last22=Mandelli|first22=F|title=Acute megakaryoblastic leukemia: experience of GIMEMA trials|journal=Leukemia|volume=16|issue=9|year=2002|pages=1622–1626|issn=0887-6924|doi=10.1038/sj.leu.2402618}}</ref> | ||
===Complications:=== | ===<u>Complications:</u>=== | ||
==='''Prognosis:'''=== | ==='''<u>Prognosis:</u>'''=== | ||
Apart from AMKL in Down syndrome patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity. | Apart from AMKL in Down syndrome patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity. | ||
Revision as of 20:53, 18 April 2021
Acute megakaryoblastic leukemia Microchapters |
Differentiating Acute megakaryoblastic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Acute megakaryoblastic leukemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Acute megakaryoblastic leukemia natural history, complications and prognosis |
FDA on Acute megakaryoblastic leukemia natural history, complications and prognosis |
CDC on Acute megakaryoblastic leukemia natural history, complications and prognosis |
Acute megakaryoblastic leukemia natural history, complications and prognosis in the news |
Blogs on Acute megakaryoblastic leukemia natural history, complications and prognosis |
Directions to Hospitals Treating Acute megakaryoblastic leukemia |
Natural History:
- Clonal proliferation of early megakaryoblasts in the bone marrow results in acute megakaryoblastic leukemia (AMKL).[1] It has a bimodal onset of presentation—occurs both in the pediatric age group (<4 years) and adults.[2]
- In childhood, it is more prevalent in patients with Down syndrome. While it is rare in adults, approximately 0.6% (24/3603) reported in the GIMEMA trial.[3]
Complications:
Prognosis:
Apart from AMKL in Down syndrome patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.
- According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and overall survival rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.[4]
- Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.[5]
- The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 Acute Myeloid leukemia subtypes.[6] Currently, chemotherapy and Allo-BMT are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.
References
- ↑ Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH; et al. (2000). "Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience". Blood. 96 (7): 2405–11. PMID 11001891.
- ↑ Gassmann, Winfried; Löffler, Helmut (2009). "Acute Megakaryoblastic Leukemia". Leukemia & Lymphoma. 18 (sup1): 69–73. doi:10.3109/10428199509075307. ISSN 1042-8194.
- ↑ Pagano, L; Pulsoni, A; Vignetti, M; Mele, L; Fianchi, L; Petti, MC; Mirto, S; Falcucci, P; Fazi, P; Broccia, G; Specchia, G; Di Raimondo, F; Pacilli, L; Leoni, P; Ladogana, S; Gallo, E; Venditti, A; Avanzi, G; Camera, A; Liso, V; Leone, G; Mandelli, F (2002). "Acute megakaryoblastic leukemia: experience of GIMEMA trials". Leukemia. 16 (9): 1622–1626. doi:10.1038/sj.leu.2402618. ISSN 0887-6924.
- ↑ Taub, Jeffrey W.; Berman, Jason N.; Hitzler, Johann K.; Sorrell, April D.; Lacayo, Norman J.; Mast, Kelley; Head, David; Raimondi, Susana; Hirsch, Betsy; Ge, Yubin; Gerbing, Robert B.; Wang, Yi-Cheng; Alonzo, Todd A.; Campana, Dario; Coustan-Smith, Elaine; Mathew, Prasad; Gamis, Alan S. (2017). "Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial". Blood. 129 (25): 3304–3313. doi:10.1182/blood-2017-01-764324. ISSN 0006-4971.
- ↑ Qi, Haixiao; Mao, Yan; Cao, Qian; Sun, Xingzhen; Kuai, Wenxia; Song, Junhong; Ma, Li; Hong, Ze; Hu, Jian; Zhou, Guoping (2020). "Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia". Medical Science Monitor. 26. doi:10.12659/MSM.922662. ISSN 1643-3750.
- ↑ Giri, Smith; Pathak, Ranjan; Prouet, Philippe; Li, Bojia; Martin, Mike G. (2014). "Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia". Blood. 124 (25): 3833–3834. doi:10.1182/blood-2014-09-603415. ISSN 0006-4971.